Citation

Xiong Y, Mahmood A, Chopp M. Discov Med 2010; 10(54): 434-442.

Affiliation

Department of Neurosurgery, Henry Ford Health System, 2799 W. Grand Blvd., Detroit, Michigan 48202, USA. michael.chopp@gmail.com.

Copyright

(Copyright © 2010, Discovery Medicine)

DOI

unavailable

PMID

21122475

PMCID

PMC3122155

Abstract

Traumatic brain injury (TBI) remains a major cause of death and permanent disability worldwide, especially in children and young adults. A total of 1.5 million people experience head trauma each year in the United States, with an annual economic cost exceeding $56 billion. Unfortunately, almost all Phase III TBI clinical trials have yet to yield a safe and effective neuroprotective treatment, raising questions regarding the use of neuroprotective strategies as the primary therapy for acute brain injuries. Recent preclinical data suggest that neurorestorative strategies that promote angiogenesis (formation of new blood vessels from pre-existing endothelial cells), axonal remodeling (axonal sprouting and pruning), neurogenesis (generation of new neurons) and synaptogenesis (formation of new synapses) provide promising opportunities for the treatment of TBI. This review discusses select cell-based and pharmacological therapies that activate and amplify these endogenous restorative brain plasticity processes to promote both repair and regeneration of injured brain tissue and functional recovery after TBI.

Language: en